ADDC could play a bigger role in the micrometastatic (adjuvant) setting, where the bulky of disease and tumor-induced immunosuppression are lower than in the metastatic setting; thereby, the level of HER2 expression in the tumor is less important for trastuzumab activity [19,20]. The gene discussed is ERBB2; the disease is neoplasm.